Want to see COYA full AI Analyst Report?
Top Page
Coya Therapeutics, Inc.
(NASDAQ:COYA)
Select Model
Select Model
Rating:49Neutral
Price Target:
$4.00
▼(-20.63% Downside)
Action:Reiterated
Date:10/05/26
The score is held down primarily by weak financial performance (large operating losses and substantial cash burn), despite a debt-free balance sheet and strong recent revenue growth. Technicals are neutral with only mild positive momentum, valuation is limited by a negative P/E and no dividend yield, and recent corporate events provide a meaningful but not decisive positive lift due to clinical trial enrollment completion ahead of upcoming data.
Positive Factors
Debt-free balance sheet
The absence of reported debt reduces borrowing-related financial risk and avoids interest obligations that could further pressure liquidity. This gives Coya greater flexibility to direct available resources toward clinical development while preserving options for future financing.
Negative Factors
Severe operating losses
Extremely negative operating results show that Coya has not yet established a sustainable earnings model despite recent revenue growth. Continued losses can limit internal reinvestment capacity, increase reliance on external capital, and make future performance highly dependent on clinical and commercial progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The absence of reported debt reduces borrowing-related financial risk and avoids interest obligations that could further pressure liquidity. This gives Coya greater flexibility to direct available resources toward clinical development while preserving options for future financing.
Read all positive factors
Coya Therapeutics, Inc. (COYA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$98.76M
Dividend YieldN/A
Average Volume (3M)151.37K
Price to Earnings (P/E)―
Beta (1Y)1.43
Revenue Growth1793.76%
EPS Growth19.33%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.07
Shares Outstanding23,457,850
10 Day Avg. Volume151,972
30 Day Avg. Volume151,374
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.26
Price to Sales (P/S)12.21
P/FCF Ratio-9.04
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue11.73
Enterprise Value/Gross Profit11.74
Enterprise Value/Ebitda-4.26
Forecast
1Y Price Target
$15.75Price Target Upside212.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.35
Revenue Forecast (FY)$1.07M
Coya Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biolo...
Coya Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.02M | 7.95M | 3.55M | 6.00M | 0.00 | 0.00 |
| Gross Profit | 8.01M | 7.92M | -8.31M | 500.68K | -4.41M | 0.00 |
| EBITDA | -22.07M | -21.20M | -17.20M | -7.33M | -9.26M | -4.88M |
| Net Income | -21.67M | -21.23M | -14.88M | -7.99M | -12.24M | -4.89M |
Balance Sheet | ||||||
| Total Assets | 47.31M | 49.95M | 44.35M | 41.26M | 8.40M | 4.79M |
| Cash, Cash Equivalents and Short-Term Investments | 43.18M | 46.82M | 38.34M | 32.63M | 5.93M | 4.34M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 12.97M | 0.00 |
| Total Liabilities | 4.03M | 6.92M | 4.77M | 5.63M | 16.79M | 1.15M |
| Stockholders Equity | 43.28M | 43.03M | 39.58M | 35.64M | -8.39M | 3.64M |
Cash Flow | ||||||
| Free Cash Flow | -13.68B | -10.74M | -10.29M | -11.19M | -7.24M | -4.04M |
| Operating Cash Flow | -13.68B | -10.74M | -10.29M | -11.19M | -7.24M | -3.90M |
| Investing Cash Flow | -887.82M | -1.16M | -25.00K | -543.19K | -525.00K | -136.80K |
| Financing Cash Flow | 21.79B | 20.39M | 16.03M | 38.43M | 9.36M | -340.58K |
Coya Therapeutics, Inc. Technical Analysis
Negative
5.04
Price Trends
4.72
Negative
4.78
Negative
4.67
Negative
Market Momentum
-0.18
Positive
34.70
Neutral
5.70
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COYA, the sentiment is Negative. The current price of 5.04 is above the 20-day moving average (MA) of 4.65, above the 50-day MA of 4.72, and above the 200-day MA of 4.67, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 34.70 is Neutral, neither overbought nor oversold. The STOCH value of 5.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COYA.
Coya Therapeutics, Inc. Risk Analysis
Coya Therapeutics, Inc. disclosed 79 risk factors in its most recent earnings report. Coya Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Coya Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $71.05M | 8.36 | 16.17% | 0.52% | 26.04% | ― | |
56 Neutral | $586.12M | -10.94 | -43.57% | ― | -66.63% | 57.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $98.76M | -3.87 | -53.32% | ― | 1793.76% | 19.33% | |
43 Neutral | $104.43M | -0.68 | -1005.80% | 0.36% | -100.00% | 54.89% | |
42 Neutral | $42.39M | -0.55 | -685.96% | ― | ― | 11.96% | |
42 Neutral | $125.34M | -1.11 | -39.64% | ― | ― | -6.70% |
* Healthcare Sector Average
COYA
Coya Therapeutics, Inc.
4.14
-2.16
-34.29%
INO
Inovio Pharmaceuticals
0.84
-1.49
-64.03%
SPRO
Spero Therapeutics
1.13
-1.08
-48.87%
ANVS
Annovis Bio
0.99
-1.06
-51.66%
NKTX
Nkarta
1.74
-0.67
-27.80%
STTK
Shattuck Labs
5.60
3.68
191.67%
Coya Therapeutics, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Coya launches open-label ALS extension, reprioritizes pipeline
Neutral
Oct 14, 2026
On October 14, 2026, Coya Therapeutics said it will launch an open-label extension of its Phase 2/3 ALSTARS Trial of COYA 302 in amyotrophic lateral sclerosis, in response to requests from investigators and participants. The extension, expected to...
Business Operations and StrategyProduct-Related Announcements
Coya Therapeutics Completes Enrollment in ALSTARS ALS Trial
Positive
Oct 5, 2026
On October 5, 2026, Coya Therapeutics announced it had fully enrolled the planned 120 patients in its ongoing Phase 2/3 ALSTARS Trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis. Additional screened participants may stil...
Business Operations and StrategyProduct-Related Announcements
Coya Therapeutics Advances COYA 302 ALS Phase 2/3 Trial
Positive
Sep 15, 2026
On September 15, 2026, Coya Therapeutics reported that the one hundredth patient has been enrolled in its ongoing Phase 2/3 ALSTARS Trial of COYA 302 for amyotrophic lateral sclerosis. The randomized, multi-center, double-blind, placebo-controlled...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.